Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of press release titled, ‘Akums reports Q4 FY26 and full year FY26 results with healthy top line and strong EBITDA growth; Board recommends dividend’.
The above information is a part of company’s filings submitted to BSE.